KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Other Non Operating Income (2018 - 2025)

Historic Other Non Operating Income for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $677000.0.

  • Esperion Therapeutics' Other Non Operating Income fell 5726.01% to $677000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $732000.0, marking a year-over-year increase of 10153.16%. This contributed to the annual value of -$54.9 million for FY2024, which is 113795.12% down from last year.
  • As of Q3 2025, Esperion Therapeutics' Other Non Operating Income stood at $677000.0, which was down 5726.01% from $666000.0 recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Other Non Operating Income registered a high of $3.9 million during Q4 2021, and its lowest value of -$53.2 million during Q2 2024.
  • In the last 5 years, Esperion Therapeutics' Other Non Operating Income had a median value of $677000.0 in 2025 and averaged -$1.9 million.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first skyrocketed by 1631250.0% in 2021, then plummeted by 330692.77% in 2024.
  • Esperion Therapeutics' Other Non Operating Income (Quarter) stood at $3.9 million in 2021, then plummeted by 65.6% to $1.4 million in 2022, then dropped by 20.3% to $1.1 million in 2023, then plummeted by 255.83% to -$1.7 million in 2024, then soared by 140.23% to $677000.0 in 2025.
  • Its last three reported values are $677000.0 in Q3 2025, $666000.0 for Q2 2025, and $1.1 million during Q1 2025.